Like this article?
Get your free daily medical news from Physician's First Watch.
FDA Approves First in New Class of Hypertension Drugs
The FDA yesterday approved Tekturna (aliskiren), the first antihypertensive drug that works by directly inhibiting renin.
In clinical trials, Tekturna was shown to be effective in patients with mild-to-moderate hypertension, with slightly smaller blood pressure reductions for African Americans than for Caucasians and Asians. The drug's safety was assessed in almost 6500 patients, the FDA said; side effects were typically mild and brief, though rare allergic reactions were observed, and the drug is contraindicated in pregnancy.
The manufacturer expects the drug to be available this month as once-daily 150 mg and 300 mg tablets. It plans to conduct large outcome trials to evaluate the drug's long-term effects.
Link: FDA press release (Free)
Link: Manufacturer press release (Free)
Published in Physician's First Watch March 7, 2007
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.